Why Some People May Be Vulnerable to Suicidal Effects of CB1 Blockers
CB1 inverse agonists like rimonabant produced impulsivity in rats only when serotonin signaling was already disrupted, suggesting people with pre-existing serotonin deficits may be vulnerable to suicidal side effects.
Quick Facts
What This Study Found
CB1 receptor inverse agonists like rimonabant showed promise as appetite suppressants but were withdrawn because they produced suicidal behavior in a small subpopulation during clinical trials. This study investigated why only some individuals were affected.
The researchers found that the CB1 inverse agonist AM 251 produced impulsivity in rats only when the serotonin 5HT1A receptor was simultaneously blocked. Without serotonin disruption, the CB1 blocker alone did not cause impulsive behavior.
Importantly, a neutral CB1 antagonist (AM 6527, which blocks without inverse agonism) did not produce impulsivity even with serotonin disruption. A peripherally restricted CB1 antagonist (AM 6545, which does not enter the brain) also had no effect.
These findings suggest that the suicidal side effects of rimonabant may have occurred specifically in people who already had compromised serotonin signaling, and that neutral CB1 antagonists (rather than inverse agonists) may be safer alternatives.
Key Numbers
AM 251 (inverse agonist) + WAY (5HT1A antagonist) produced impulsivity on both tasks. AM 6527 (neutral antagonist) + WAY showed mild effects on one task only. AM 6545 (peripheral) had no effects.
How They Did This
Male Sprague Dawley rats were tested on two behavioral tasks measuring impulsivity (paced fixed consecutive number task and a novel variable consecutive number task) after receiving CB1 inverse agonist, antagonist, or peripherally restricted antagonist, with or without the serotonin 5HT1A antagonist WAY 100,635.
Why This Research Matters
Rimonabant's withdrawal was a major setback for cannabinoid-based obesity medicine. Understanding that the dangerous side effects required pre-existing serotonin vulnerability opens a path forward: either screening patients for serotonin risk or using neutral antagonists instead of inverse agonists.
The Bigger Picture
This study provides a mechanistic explanation for the rimonabant crisis and demonstrates that the endocannabinoid and serotonin systems interact in clinically dangerous ways. It also shows that not all CB1 blockers are equal: neutral antagonists may avoid the serotonin interaction.
What This Study Doesn't Tell Us
Animal model of impulsivity may not fully capture human suicidal ideation. The serotonin blockade was pharmacologically induced rather than representing natural variation. Only male rats were tested.
Questions This Raises
- ?Could serotonin function be screened before prescribing CB1-targeting medications?
- ?Would people on SSRIs (which affect serotonin) be protected from or vulnerable to these effects?
- ?Are neutral CB1 antagonists effective enough as appetite suppressants to be clinically useful?
Trust & Context
- Key Stat:
- CB1 inverse agonists caused impulsivity only when serotonin signaling was already disrupted
- Evidence Grade:
- Controlled animal pharmacology study. Preliminary but provides an important mechanistic explanation for a known clinical problem.
- Study Age:
- Published in 2017.
- Original Title:
- Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.
- Published In:
- Psychopharmacology, 234(6), 1029-1043 (2017)
- Authors:
- McLaughlin, Peter J, Jagielo-Miller, Julia E, Plyler, Emily S, Schutte, Kerry K, Vemuri, V Kiran, Makriyannis, Alexandros
- Database ID:
- RTHC-01454
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why was rimonabant dangerous?
Rimonabant, a CB1 inverse agonist, caused suicidal behavior in some patients. This study suggests this happened because inverse agonism combined with pre-existing serotonin deficits created impulsivity, and that neutral CB1 antagonists may avoid this problem.
Could CB1 blockers still be used for weight loss?
This study suggests neutral CB1 antagonists (which block the receptor without inverse agonism) and peripherally restricted compounds may be safer alternatives that avoid the serotonin interaction responsible for suicidal side effects.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01454APA
McLaughlin, Peter J; Jagielo-Miller, Julia E; Plyler, Emily S; Schutte, Kerry K; Vemuri, V Kiran; Makriyannis, Alexandros. (2017). Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.. Psychopharmacology, 234(6), 1029-1043. https://doi.org/10.1007/s00213-017-4548-2
MLA
McLaughlin, Peter J, et al. "Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.." Psychopharmacology, 2017. https://doi.org/10.1007/s00213-017-4548-2
RethinkTHC
RethinkTHC Research Database. "Differential effects of cannabinoid CB1 inverse agonists and..." RTHC-01454. Retrieved from https://rethinkthc.com/research/mclaughlin-2017-differential-effects-of-cannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.